146 related articles for article (PubMed ID: 29358623)
1. Targeted reduction of the EGFR protein, but not inhibition of its kinase activity, induces mitophagy and death of cancer cells through activation of mTORC2 and Akt.
Katreddy RR; Bollu LR; Su F; Xian N; Srivastava S; Thomas R; Dai Y; Wu B; Xu Y; Rea MA; Briggs JM; Zhang Q; Lu X; Huang G; Weihua Z
Oncogenesis; 2018 Jan; 7(1):5. PubMed ID: 29358623
[TBL] [Abstract][Full Text] [Related]
2. Kinase-Inactivated EGFR Is Required for the Survival of Wild-Type EGFR-Expressing Cancer Cells Treated with Tyrosine Kinase Inhibitors.
Thomas R; Srivastava S; Katreddy RR; Sobieski J; Weihua Z
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31121829
[TBL] [Abstract][Full Text] [Related]
3. Rethink of EGFR in Cancer With Its Kinase Independent Function on Board.
Thomas R; Weihua Z
Front Oncol; 2019; 9():800. PubMed ID: 31508364
[TBL] [Abstract][Full Text] [Related]
4. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
Phuchareon J; McCormick F; Eisele DW; Tetsu O
Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3855-63. PubMed ID: 26150526
[TBL] [Abstract][Full Text] [Related]
5. Effects of hyperinsulinemia on acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor via the PI3K/AKT pathway in non-small cell lung cancer cells
Chiu HY; Chiang CM; Yeh SP; Jong DS; Wu LS; Liu HC; Chiu CH
Oncol Lett; 2020 Nov; 20(5):206. PubMed ID: 32963612
[TBL] [Abstract][Full Text] [Related]
6. Role of HGF/MET axis in resistance of lung cancer to contemporary management.
Raghav KP; Gonzalez-Angulo AM; Blumenschein GR
Transl Lung Cancer Res; 2012 Sep; 1(3):179-93. PubMed ID: 25806180
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
[TBL] [Abstract][Full Text] [Related]
8. EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors.
Ren J; Bollu LR; Su F; Gao G; Xu L; Huang WC; Hung MC; Weihua Z
Prostate; 2013 Sep; 73(13):1453-61. PubMed ID: 23765757
[TBL] [Abstract][Full Text] [Related]
9. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
10. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
[TBL] [Abstract][Full Text] [Related]
11. Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer.
Jacobsen K; Bertran-Alamillo J; Molina MA; Teixidó C; Karachaliou N; Pedersen MH; Castellví J; Garzón M; Codony-Servat C; Codony-Servat J; Giménez-Capitán A; Drozdowskyj A; Viteri S; Larsen MR; Lassen U; Felip E; Bivona TG; Ditzel HJ; Rosell R
Nat Commun; 2017 Sep; 8(1):410. PubMed ID: 28871105
[TBL] [Abstract][Full Text] [Related]
12. Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations.
Yamada T; Takeuchi S; Fujita N; Nakamura A; Wang W; Li Q; Oda M; Mitsudomi T; Yatabe Y; Sekido Y; Yoshida J; Higashiyama M; Noguchi M; Uehara H; Nishioka Y; Sone S; Yano S
Oncogene; 2013 Sep; 32(37):4427-35. PubMed ID: 23045273
[TBL] [Abstract][Full Text] [Related]
13. Targeting Autophagy for Overcoming Resistance to Anti-EGFR Treatments.
Kwon Y; Kim M; Jung HS; Kim Y; Jeoung D
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31527477
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells.
Zhou C; Qiu L; Sun Y; Healey S; Wanebo H; Kouttab N; Di W; Yan B; Wan Y
Int J Oncol; 2006 Jul; 29(1):269-78. PubMed ID: 16773209
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Thibault B; Jean-Claude B
J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
[TBL] [Abstract][Full Text] [Related]
16. PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy.
To KKW; Wu WKK; Loong HHF
Eur J Pharmacol; 2018 Mar; 823():19-26. PubMed ID: 29378193
[TBL] [Abstract][Full Text] [Related]
17. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
18. IGFBP7 Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung Cancer.
Wu SG; Chang TH; Tsai MF; Liu YN; Hsu CL; Chang YL; Yu CJ; Shih JY
Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30609749
[TBL] [Abstract][Full Text] [Related]
19. Repression of Human Papillomavirus Oncogene Expression under Hypoxia Is Mediated by PI3K/mTORC2/AKT Signaling.
Bossler F; Kuhn BJ; Günther T; Kraemer SJ; Khalkar P; Adrian S; Lohrey C; Holzer A; Shimobayashi M; Dürst M; Mayer A; Rösl F; Grundhoff A; Krijgsveld J; Hoppe-Seyler K; Hoppe-Seyler F
mBio; 2019 Feb; 10(1):. PubMed ID: 30755508
[TBL] [Abstract][Full Text] [Related]
20. High mannose-binding Pseudomonas fluorescens lectin (PFL) downregulates cell surface integrin/EGFR and induces autophagy in gastric cancer cells.
Sato Y; Kubo T; Morimoto K; Yanagihara K; Seyama T
BMC Cancer; 2016 Feb; 16():63. PubMed ID: 26850110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
